Trial Profile

SOLIRIS® (Eculizumab) for the Treatment of Participants With Coronavirus Disease 2019 (COVID 19) - An Expanded Access Program for Hospital-based Emergency Treatment

Status: Completed

Phase of Trial: Clinical Phase Unknown

Latest Information Update: 06 Nov 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Eculizumab (Primary)
Indications Acute lung injury; Adult respiratory distress syndrome; COVID 2019 infections; Pneumonia
Focus Expanded access; Therapeutic Use
Sponsors Alexion AstraZeneca Rare Disease

Most Recent Events

25 Jul 2022 Results (n=8) evaluating eculizumab for treatment of severe COVID-19 in pregnant and postpartum individuals, published in the American Journal of Reproductive Immunology
05 Mar 2021 Status changed from recruiting to completed.
23 Apr 2020 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com